They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

CagriSema – a combination of Novo Nordisk's GLP-1 agonist semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – achieved a 20.4% reduction in weight in the REDEFINE 1 ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

If not administered properly, the GLP-1 medication can cause nausea, abdominal pain, and cramps, possibly leading to dehydration. The doses are normally taken a week apart, so not waiting long enough ...